Sutro Biopharma (STRO) — Cash Flow Quality Index
Sutro Biopharma (STRO) has a Cash Flow Quality Index of 0.45x as of December 2023. Operating cash flow of $14.07 Million is below net income of $31.07 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore STRO cash generation efficiency to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Sutro Biopharma Cash Flow Quality Index (2016–2016)
Historical Cash Flow Quality Index for Sutro Biopharma across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Sutro Biopharma total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Sutro Biopharma (2016–2016)
Year-by-year earnings quality comparison for Sutro Biopharma. For live market cap and the full company financial profile, see STRO market cap.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2016 | -7.73x | $-13.15 Million | $1.70 Million | — |